Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase NA 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Leukemia, Myeloid, Acute 143Myelodysplastic Syndromes 53Leukemia 24Leukemia, Myelomonocytic, Chronic 21Recurrence 12Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Peripheral 6Leukemia, Monocytic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Prostatic Neoplasms 3Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pancreatic Neoplasms 2

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Azacitidine × Clear all
NCT04891068 2026-01-14

BRE-04

University of Illinois at Chicago

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
58 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Celgene

Phase 2 Terminated
97 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡